Overview

• Boehringer Ingelheim's 2024 revenue grew by 6.1%, reaching 26.8 billion euros, with human pharmaceuticals contributing 21.9 billion euros, a 7% increase.
• Jardiance, the company's top-selling product, generated 8.4 billion euros in revenue, a 14% rise, driven by its use in diabetes, heart failure, and kidney disease treatments.
• The company invested 6.2 billion euros in research and development, with 5.7 billion euros allocated to human pharmaceuticals, supporting innovation in oncology and respiratory diseases.
• Plans are underway to potentially launch Zongertinib for lung cancer and Nerandomilast for lung fibrosis in 2025, reflecting a focus on unmet medical needs.
• Boehringer Ingelheim continues to regionalize its supply chains, including establishing a localized supply chain for Jardiance in the U.S., to mitigate trade risks.